Linden Thomas Advisory Services LLC Buys 1,300 Shares of Corcept Therapeutics Incorporated (NASDAQ:CORT)

Linden Thomas Advisory Services LLC raised its position in shares of Corcept Therapeutics Incorporated (NASDAQ:CORT) by 2.1% in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 63,224 shares of the biotechnology company’s stock after acquiring an additional 1,300 shares during the period. Linden Thomas Advisory Services LLC owned approximately 0.06% of Corcept Therapeutics worth $3,186,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently made changes to their positions in CORT. Inspire Investing LLC bought a new stake in Corcept Therapeutics in the 4th quarter valued at $807,000. Nisa Investment Advisors LLC increased its position in Corcept Therapeutics by 8.3% during the 4th quarter. Nisa Investment Advisors LLC now owns 10,665 shares of the biotechnology company’s stock worth $537,000 after buying an additional 814 shares during the period. Ballentine Partners LLC acquired a new stake in shares of Corcept Therapeutics during the fourth quarter worth $200,000. USA Financial Formulas bought a new stake in shares of Corcept Therapeutics in the fourth quarter valued at about $54,000. Finally, Burney Co. grew its stake in shares of Corcept Therapeutics by 9.1% in the fourth quarter. Burney Co. now owns 473,821 shares of the biotechnology company’s stock valued at $23,876,000 after acquiring an additional 39,657 shares in the last quarter. Institutional investors and hedge funds own 93.61% of the company’s stock.

Wall Street Analyst Weigh In

Several analysts have weighed in on CORT shares. StockNews.com cut shares of Corcept Therapeutics from a “strong-buy” rating to a “buy” rating in a research note on Monday, November 25th. Truist Financial lifted their price target on shares of Corcept Therapeutics from $65.00 to $76.00 and gave the company a “buy” rating in a research report on Monday, September 30th. HC Wainwright reissued a “buy” rating and set a $80.00 price target on shares of Corcept Therapeutics in a research report on Thursday, October 31st. Finally, Sandler O’Neill reaffirmed a “buy” rating on shares of Corcept Therapeutics in a report on Friday, October 18th. Six analysts have rated the stock with a buy rating, According to MarketBeat.com, Corcept Therapeutics presently has a consensus rating of “Buy” and an average target price of $65.25.

Insider Buying and Selling

In other Corcept Therapeutics news, Director Daniel N. Swisher, Jr. sold 2,200 shares of the firm’s stock in a transaction that occurred on Monday, November 11th. The shares were sold at an average price of $59.88, for a total value of $131,736.00. The sale was disclosed in a document filed with the SEC, which is available at this link. Also, insider Joseph Douglas Lyon sold 1,411 shares of the company’s stock in a transaction on Friday, November 22nd. The stock was sold at an average price of $56.72, for a total transaction of $80,031.92. Following the transaction, the insider now owns 8,494 shares of the company’s stock, valued at $481,779.68. This trade represents a 14.25 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 38,011 shares of company stock worth $1,951,268 in the last ninety days. 20.50% of the stock is owned by insiders.

Corcept Therapeutics Price Performance

Shares of NASDAQ:CORT opened at $59.99 on Friday. The company has a current ratio of 3.70, a quick ratio of 3.64 and a debt-to-equity ratio of 0.01. The stock has a market capitalization of $6.29 billion, a PE ratio of 47.61 and a beta of 0.56. The firm has a 50 day moving average of $55.16 and a 200-day moving average of $45.77. Corcept Therapeutics Incorporated has a 12 month low of $20.84 and a 12 month high of $62.98.

Corcept Therapeutics (NASDAQ:CORT) last announced its quarterly earnings data on Wednesday, October 30th. The biotechnology company reported $0.41 EPS for the quarter, beating the consensus estimate of $0.27 by $0.14. The business had revenue of $182.55 million during the quarter, compared to the consensus estimate of $171.97 million. Corcept Therapeutics had a net margin of 22.35% and a return on equity of 24.54%. The company’s revenue was up 47.7% on a year-over-year basis. During the same period in the previous year, the business earned $0.28 earnings per share. On average, equities research analysts predict that Corcept Therapeutics Incorporated will post 1.35 EPS for the current fiscal year.

Corcept Therapeutics Profile

Corcept Therapeutics Incorporated engages in discovery and development of drugs for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. It offers Korlym tablets medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous cushing's syndrome; and who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery.